Introduction
We present a case of a patient with well-controlled human immunodeficiency virus (HIV) infection and refractory classical Hodgkin lymphoma (HL) treated with nivolumab as fifth-line treatment, who achieved complete response (CR) by positron emission tomography/computed tomography (PET/CT). To our knowledge, this is the second case report of a patient exhibiting nivolumab's response, and the first reported CR in the setting of HIV-associated HL (HIV-HL).
Case Report
A 40-year-old veteran was diagnosed with HIV in 2009. His CD4 count was 290 cells/mm 3 . After initiation of antiretroviral therapy with efavirenz/emtricitabine/tenofovir disoproxil (Atripla), he maintained good disease control for the next 6 years, with consistently undetectable viral loads and no serious infections. When he initially noticed a right axillary mass in the summer of 2015, he delayed seeking medical attention. On presentation in the Fall of 2015, he had lost 15 pounds over 10 weeks, and his CD4 count had dropped from 593 to 353 cells/mm 3 .
His HIV physician ordered a CT scan of the neck and chest, which revealed bilateral axillary (up to 3.9 cm), retropectoral, and infraclavicular lymphadenopathy. An excisional biopsy of the left axillary node showed HL, nodular sclerosis type, Epstein-Barr virus (EBV)-LMP1, and Epstein-Barr encoding region in-situ hybridization positive (Figure 1 ). EBV viral load was not evaluated at this time. His bone marrow biopsy was negative for lymphoma. Scans of the abdomen and pelvis showed no lymphadenopathy below the diaphragm. Erythrocyte sedimentation rate was more than 100 mm/hr.
Thus, he was diagnosed with stage IIB classical HL. His baseline echocardiogram was concerning for a left ventricular ejection fraction of 45%, which was confirmed on multigated acquisition scan. To avoid anthracycline-induced worsening left ventricular function, he was treated with 6 cycles of cyclophosphamide, vincristine, prednisone, and procarbazine (COPP). The posttreatment F-18 fluorodeoxyglucose (FDG) PET/CT scan demonstrated active
Clinical Practice Points
We present a case of a veteran with well-controlled human immunodeficiency virus (HIV) infection and primary refractory classical Hodgkin lymphoma (HL) who, after multiple prior lines of therapy, received nivolumab with a complete response. He also developed autoimmune diabetes mellitus after 6 months of nivolumab. HIV-associated HL is currently treated under the same algorithm as HL in the general population, but its unique biology, particularly the near-universal association with Epstein-Barr virus, regardless of histology, suggests that immunotherapy may have an important role in the management of this disease. Most clinical trials highlighting checkpoint inhibitors have excluded HIV-infected patients. More prospective data is clearly needed to delineate the risks and benefits of immunotherapy in this population with increased autoimmunity at baseline.
lymphomatous disease throughout the right cervical, axillary, and subpectoral regions (Figure 2A) . Biopsy of the right axillary lymph node confirmed refractory HL.
His primary refractory disease progressed through 3 more regimens: (1) brentuximab vedotin (hereafter called simply "brentuximab"), (2) brentuximab in combination with gemcitabine, and (3) ifosfamide/carboplatin/etoposide (ICE). The patient was then offered nivolumab. After 8 cycles (3 mg/kg every 2 weeks), the posttreatment PET/CT demonstrated resolution of previous abnormal uptake and nodal size consistent with complete response by International Working Group criteria 1 ( Figure 2B ). He currently has no lymphoma-related symptoms, and has received a total of 17 cycles by the time of this report. His CD4 count, 391 cells/mm 3 at the start of therapy and now 426 cells/mm 3 , has remained stable throughout this time; the viral load has remained undetectable. The antiretroviral regimen was changed from Atripla to an integrase inhibitor-based regimen, tenofovir alafenamide/emtricitabine/dolutegravir, for noncancer-or chemotherapy-related reasons. However, he developed insulin-dependent diabetes mellitus with the presence of glutamic acid decarboxylase antibodies. He has declined evaluation for autologous stem cell transplant.
Discussion
The pathogenesis of lymphoma in HIV is complex. HIV not only increases the risk of cancer through immunosuppression, but is also a carcinogen in itself. 2 Although the distribution of histologic subtypes may have shifted slightly in the last 20 years with the widespread use of antiretroviral therapy, 3 the overall incidence of HIV-HL has not significantly decreased, in contrast to dramatic decreases in the rates of Kaposi sarcoma, primary central nervous system lymphoma, and diffuse large B-cell lymphoma, suggesting that antiretroviral therapy-mediated immune reconstitution is not adequate to prevent Hodgkin lymphomagenesis in the HIVinfected population. 4 Additionally, the observation that EBV is invariably detectable in HIV-HL regardless of histology, [5] [6] [7] and is only seen in 20% to 40% of classical HL cases in the HIVuninfected population, has sparked research interest in the tumor microenvironment of HIV-HL in search of the unique role of EBV in this disease. In the meantime, HIV-HL is treated under the same guidelines as classical HL in the general population. Among patients with HIV-HL with nodular sclerosis or mixed cellularity histology who receive chemotherapy, survival is comparable to patients without HIV. However, because treatment in patients who are HIV-infected is more frequently withheld, outcomes for HIV-HL are worse than those seen in HIV-uninfected patients on average. 3 Immune checkpoint blockade emerged as an important new treatment option for patients with relapsed or refractory HL in 2015, after a pivotal single-arm multicenter trial of nivolumab monotherapy demonstrated an impressive objective response rate of 87%. 8 In 2016, nivolumab was granted United States Food and Drug Administration approval for relapsed or refractory HL after autologous stem cell transplant, followed by publication of a second single-arm, multicenter trial demonstrating an objective response rate of 66%. 9 However, the safety and efficacy of nivolumab in HIV-HL are still unknown, because the first trial excluded patients with HIV infection, and the second trial did not report HIV status. The scientific rationale for checkpoint therapy in HL is clear, as chromosome 9p24.1/programmed death-ligand (PD-L)1/PD-L2 alterations, increasing the abundance of the PD-L1 and PD-L2 HIV-HL Case: Response to Nivolumab ligands, are seen when evaluated by fluorescence in situ hybridization assay in nearly all patients with HL. Furthermore, these copy number alterations are a defining feature of the disease. Interestingly, EBV induces PD-L1 expression even in patients with normal 9p24.1 copy numbers in HL. 10 The role of EBV in inducing PD-L1 expression is further demonstrated outside HL. In one study, 100% of EBV-positive immunodeficiency-associated diffuse large B-cell lymphomas were found to express PD-L1. 11 This is particularly significant given the 3-fold stronger association with EBV in HIV-HL compared with classical HL in HIV-uninfected patients. Our patient's tumor was strongly positive for EBV by both LMP1 immunohistochemistry and Epstein-Barr encoding region in-situ hybridization suggesting a "primed" state for immune checkpoint response. Finally, HIV infection itself seems to induce a state of immunosuppression and immune evasion mediated by the programmed cell death protein 1 (PD-1)ePD-L1 axis. 12, 13 In patients with chronic HIV infection, longitudinal assessment shows that HIVspecific CD8þ T cells upregulate PD-1 expression over time, resulting in anergy. Furthermore, blockade of the PD-1ePD-L1 pathway in vitro results in regain of HIV-specific CD8þ T cell effector function. 14 It is hypothesized that HIV-specific dysfunctional CD8þ T cells gradually accumulate and prevent the renewal of a more competent, less anergic, HIV-specific CD8þ repertoire.
Figure 1 Pathologic Analysis, With Hematoxylin and Eosin (H&E) (A), CD30 (B), LMP1 (C), and Epstein-Barr Encoding Region In-situ Hybridization (EBER ISH) (D). A, Multiple Reed-Sternberg Cells and Hodgkin Cells are Surrounded By a Mixed Cellular
14 This is consistent with findings that the gradual loss of CD4 cells in HIV infection is owing to an immune-based mechanism rather than a direct HIV cytopathic effect. 15 Our patient's CD4 count is stableto-increasing on antiePD-1 therapy, supporting our hypothesis that nivolumab may actually improve HIV-related immune dysfunction. This data suggests that it is possible that EBV and HIV induce PD-L1 expression, which leads to escape from immune surveillance, as well as diminished immune surveillance, allowing the 2 viruses to synchronously contribute to the pathogenesis of HL. 13 Because the degree of PD-L1 expression did not predict nivolumab response in clinical trials, 8 testing for PD-L1 expression was not requested on our patient's tumor. Despite multiple reasons for immune checkpoint implementation in HIV-related lymphomas, no data from clinical trials have yet been published. A phase I clinical trial evaluating the safety of combination checkpoint blockade with nivolumab and ipilimumab in the treatment of solid malignancies added an expansion cohort for HL (NCT02408861). Additionally, a second phase I clinical trial is evaluating the safety of pembrolizumab in patients with HIV infection and recurrent or refractory malignancies, including HL, NHL, and almost any solid cancer (NCT02595866). A literature search yielded only one case report of a patient with HIV infection and HL who was treated with nivolumab. 16 This patient was diagnosed with both classical HL and Burkitt lymphoma (both EBV-associated) at 42 years of age, with a baseline CD4 count of 155 cells/mm 3 and bone marrow infiltration by cHL. The Burkitt lymphoma was responsive to first-line therapy, but the classical HL continued to be refractory to salvage regimens including brentuximab. In spite of liver failure complicated by encephalopathy, he was treated with nivolumab, and had an excellent partial response. The duration of response apparently was at least 1 year, by the time of the writing of the case report, and he had experienced no immune-related adverse effects.
Conclusion
We present the first reported case of a CR to nivolumab in a patient with HIV-HL. There has been only one previous case report of a patient with HIV infection and HL who achieved partial response after salvage treatment with nivolumab. Of note, that patient also experienced a disease response of at least 1 year. Unfortunately, our patient developed autoimmune diabetes mellitus, which was possibly related to nivolumab toxicity. Further prospective studies need to address the role of nivolumab for HIV-HL, currently limited to posttransplant relapsed refractory settings, given the strong association with EBV and multi-faceted biological and mechanistic justifications. Additionally, the risk of immune-related adverse events needs to be further characterized.
